中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

已选(0)清除 条数/页：   排序方式：
Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 139, 期号: 无, 页码: 674-697
作者:  Chen, Yongfei;  Wu, Jiaxin;  Wang, Aoli;  Qi, Ziping;  Jiang, Taoshan;  Chen, Cheng;  Zou, Fengming;  Hu, Chen;  Wang, Wei;  Wu, Hong;  Hu, Zhenquan;  Wang, Wenchao;  Wang, Beilei;  Wang, Li;  Ren, Tao;  Zhang, Shanchun;  Liu, Qingsong;  Liu, Jing
浏览  |  Adobe PDF(12656Kb)  |  收藏  |  浏览/下载：21281/11466  |  提交时间：2018/08/17
Egfr  Alk  Dual Kinase Inhibitor  Non-small Cell Lung Cancer  
Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1,504 Chinese Han patients 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2016, 卷号: 28
-
收藏  |  浏览/下载：43/0  |  提交时间：2020/10/26
EML4-ALK FUSION  CANCER  ADENOCARCINOMA  PCR  EXPERIENCE  FISH  GENE  Anaplastic lymphoma kinase (ALK) rearrangements  fully automated immunohistochemistry (IHC)  clinicopathological analysis  targeted therapy